- Home
- KPRX vs APLM Comparison
KPRX vs APLM Comparison
Compare KPRX & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- APLM
- Stock Information
- Founded
- KPRX 1998
- APLM 2016
- Country
- KPRX United States
- APLM United States
- Employees
- KPRX N/A
- APLM N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- APLM Blank Checks
- Sector
- KPRX Health Care
- APLM Finance
- Exchange
- KPRX Nasdaq
- APLM Nasdaq
- Market Cap
- KPRX 8.3M
- APLM 7.7M
- IPO Year
- KPRX N/A
- APLM N/A
- Fundamental
- Price
- KPRX $3.18
- APLM $6.52
- Analyst Decision
- KPRX Strong Buy
- APLM Strong Buy
- Analyst Count
- KPRX 1
- APLM 1
- Target Price
- KPRX $10.00
- APLM $200.00
- AVG Volume (30 Days)
- KPRX 10.5K
- APLM 57.8K
- Earning Date
- KPRX 05-09-2025
- APLM 04-03-2025
- Dividend Yield
- KPRX N/A
- APLM N/A
- EPS Growth
- KPRX N/A
- APLM N/A
- EPS
- KPRX 0.87
- APLM N/A
- Revenue
- KPRX $16,020,000.00
- APLM $198,000.00
- Revenue This Year
- KPRX N/A
- APLM $415.15
- Revenue Next Year
- KPRX N/A
- APLM N/A
- P/E Ratio
- KPRX $3.56
- APLM N/A
- Revenue Growth
- KPRX N/A
- APLM N/A
- 52 Week Low
- KPRX $2.51
- APLM $4.71
- 52 Week High
- KPRX $5.76
- APLM $53.00
- Technical
- Relative Strength Index (RSI)
- KPRX 55.96
- APLM 46.30
- Support Level
- KPRX $2.64
- APLM $5.41
- Resistance Level
- KPRX $3.25
- APLM $6.19
- Average True Range (ATR)
- KPRX 0.19
- APLM 0.82
- MACD
- KPRX 0.06
- APLM 0.03
- Stochastic Oscillator
- KPRX 74.32
- APLM 48.05
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.